Cagrilintide + Semaglutide Blend Research Information
Amylin Analogue + GLP-1 Receptor Agonist Blend
For Metabolic & Weight Management Research
⚠️ Important: This information is for educational and research purposes only. Always consult with a qualified healthcare professional before use.
📑 Contents
🔬 What is Cagrilintide + Semaglutide Blend?
The Cagrilintide + Semaglutide blend (also known as CagriSema) is a synergistic combination of two potent metabolic peptides that work through complementary mechanisms to support weight management and metabolic health:
- • Cagrilintide – A long-acting amylin and calcitonin receptor agonist that induces satiety and reduces food intake
- • Semaglutide – A potent GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and enhances insulin secretion
This combination has been studied in clinical trials under the name CagriSema and has demonstrated enhanced weight loss effects through complementary pathways. The total blend is 10mg and is designed for research purposes. Cagrilintide + Semaglutide Blend is available in pen and freeze-dried vial formulations for research purposes.
⚡ How Cagrilintide + Semaglutide Blend Works
This blend works through two distinct but complementary mechanisms to promote weight loss and metabolic health:
Cagrilintide
Amylin/calcitonin receptor agonist that induces satiety, reduces food intake, and slows gastric emptying
Semaglutide
GLP-1 receptor agonist that reduces appetite, enhances insulin secretion, and slows gastric emptying
Together, these peptides provide enhanced appetite suppression, improved glycemic control, and synergistic weight loss effects through complementary pathways.
📋 Research Applications
Weight Management
Evaluated for synergistic weight reduction in individuals with obesity or overweight
Metabolic Health
Assessed for glycemic control and metabolic improvements
Combination Therapy
Studying additive and synergistic effects of dual receptor activation
Liver Health
Investigating effects on metabolic dysfunction-associated steatotic liver disease (MASLD)
📊 Clinical Studies
Phase 1b Combination Trial
- Cagrilintide combined with semaglutide 2.4 mg showed additive weight loss effects
- Cagrilintide 2.4 mg + Semaglutide 2.4 mg: −17.1% weight loss at 20 weeks
- Cagrilintide 1.2 mg + Semaglutide 2.4 mg: −15.7% weight loss at 20 weeks
- Semaglutide 2.4 mg monotherapy: −11.1% weight loss at 20 weeks
Phase 3 REDEFINE Trials
- CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg) once-weekly vs placebo
- −15.7% body weight reduction at 68 weeks (trial product estimand)
- 89.7% of patients achieved ≥5% weight loss
- Gastrointestinal adverse events in 79.6% (mostly transient and mild-to-moderate)
Key Research Findings
- Additive weight loss effects from combining amylin and GLP-1 agonism
- Synergistic effects on appetite suppression and glycemic control
- Demonstrated efficacy in both obesity and type 2 diabetes research models
💉 Interactive Dosing Guide
Select your blend size and dose to see the corresponding volume, clicks, dosing frequency, and how many doses per vial:
🖊️ Step 1: Select Your Blend Size
💊 Step 2: Select Your Dose
Common research protocols: 0.1-0.5 mg per dose. Phase 3 trials used 2.4 mg of each component (4.8 mg total) weekly.
Blend Size
10mg Blend
Selected Dose
0.25 mg
Doses per Vial
40 doses
Pen Clicks
7.5 clicks
Volume
0.075 mL
Protocol Level
Level 2 (Standard)
Recommended Schedule
Once weekly - Research Protocol
⚠️ Do not change your dose unless advised by a qualified professional.
📋 Protocol Level Summary
Based on research protocols: 0.1-0.5 mg per dose. Phase 3 trials used 2.4 mg of each component weekly.
| Protocol Level | Target Dose | Frequency | Pen Clicks | Volume (mL) | Who It\'s For |
|---|---|---|---|---|---|
| Level 1 (Starting) | 0.1-0.2 mg | Once weekly | 3-6 clicks | 0.03-0.06 mL | New users, first 4 weeks |
| Level 2 (Standard) | 0.25 mg | Once weekly | 7.5 clicks | 0.075 mL | After 4 weeks, maintenance |
| Level 3 (Advanced) | 0.4 mg | Once weekly | 12 clicks | 0.12 mL | If more response needed |
| Level 4 (Maximum) | 0.5 mg | Once weekly | 15 clicks | 0.15 mL | Experienced users only |
⚠️ Do not change your dose unless advised by a qualified professional.
💉 Vial Users (Insulin Syringe)
Add 3mL of bacteriostatic water to your freeze-dried vial and mix gently. After reconstitution, use the table below to draw your dose:
Vial Size
10mg blend vial with 3mL bac water
| Dose | Frequency | Units on Syringe | Volume (mL) | Protocol Level |
|---|
⚠️ Always use a new sterile needle and syringe for each injection.
⚠️ Safety & Precautions
The Cagrilintide + Semaglutide blend has shown a manageable safety profile in clinical studies. The most common adverse events are gastrointestinal side effects, which are mostly transient and mild-to-moderate.
- Gastrointestinal: Nausea, vomiting, diarrhea, constipation (transient)
- Injection site reactions: Mild redness or tenderness
- Well-tolerated: Most side effects diminish with continued use
Do not use if you:
- Are allergic to any of the components
- Are pregnant or breastfeeding
- Have type 1 diabetes
⚠️ Warning: If you experience severe allergic reactions, difficulty breathing, or signs of anaphylaxis, seek immediate medical help.
📚 References
- Phase 1b Combination Trial Data. Peptide Research.
- REDEFINE 1 Phase 3 Trial. NEJM. 2025.
- CagriSema Research Overview. Peptide Sciences.
This information is for educational and research purposes only. Always consult with a qualified healthcare professional.
Last updated: July 2026